Integrated Filing — IndAS



General information about company
Scrip Code 524372
NSE Symbol ORCHPHARMA
MSEI Symbol NOTLISTED
ISIN INE191A01027
Name of company ORCHID PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 26-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 26-May-2025   12:00:00
End date and time of board meeting 26-May-2025   15:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Statement on impact of audit qualification



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2374787000 9219259000
Other income 38972000 274747000
Total income 2413759000 9494006000
2 Expenses
(a) Cost of materials consumed 1369446000 5854606000
(b) Purchases of stock-in-trade 12440000 26131000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1724000 -438511000
(d) Employee benefit expense 222424000 863606000
(e) Finance costs 39150000 145401000
(f) Depreciation, depletion and amortisation expense 88717000 345458000
(f) Other Expenses
1 Other Expenses 492365000 1741667000
Total other expenses 492365000 1741667000
Total expenses 2222818000 8538358000
3 Total profit before exceptional items and tax 190941000 955648000
4 Exceptional items 0 0
5 Total profit before tax 190941000 955648000
6 Tax expense
7 Current tax 0 0
8 Deferred tax -394000 -1935000
9 Total tax expenses -394000 -1935000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 191335000 957583000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 31611000 38985000
16 Total profit (loss) for period 222946000 996568000
17 Other comprehensive income net of taxes 16675000 -7513000
18 Total Comprehensive Income for the period 239621000 989055000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 507191000 507191000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.4 19.65
Diluted earnings (loss) per share from continuing operations 4.4 19.65
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.4 19.65
Diluted earnings (loss) per share from continuing and discontinued operations 4.4 19.65
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above results for the quarter and year ended March 31 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 26, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. n2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. n3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. nAs on March 31, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : n Statement of QIP Net Funds raised and utilisation nParticulars Amount as stated in Total amount utilised Balance amount as on Remarks n the Offer Document upto March 31, 2025 on March 31, 2025 kept n Rs. In Lakhst Rs. In Lakhs in Fixed Deposits in lakhs n1)Investment in OBPL, subsidiary, nfor setting up Jammu nManufacturing Facilityt 9000 4416t 4584t n2)Repayment/prepayment, in nfull or in part, of certain noutstanding borrowings navailed by the companyt 14100t 14100t -t n3)Funding capital expenditure n requirements for setting up a n new block at the API facility n of the Company in Alathur, nTamil Nadut 9982 36t 9946 n4)General corporate purposes 6098t 6372t 0t _ nTotalt 39180 24924t 14530 nAs per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on then proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on March 31, 2025. n Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. n4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. n5. The figures for the quarters ended 31st March, 2025 and 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. n6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the nCompany in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, nin compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, ngiving No objection to the said amalgamation. Further, the Honourable NCLT have pronounced the order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed off the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. The management of the respective Companies are taking steps to comply with the said Order. n n7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 6315854000
Capital work-in-progress 644893000
Investment property 0
Goodwill 11253000
Other intangible assets 0
Intangible assets under development 162236000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 496706000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 42698000
Total non-current financial assets 539404000
Deferred tax assets (net) 513015000
Other non-current assets 618319000
Total non-current assets 8804974000
2 Current assets
Inventories 3263715000
Current financial asset
Current investments 0
Trade receivables, current 2418321000
Cash and cash equivalents 211068000
Bank balance other than cash and cash equivalents 1585257000
Loans, current 0
Other current financial assets 30436000
Total current financial assets 4245082000
Current tax assets (net) 27741000
Other current assets 537635000
Total current assets 8074173000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 16879147000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 507191000
Other equity 12165663000
Total equity attributable to owners of parent 12672854000
Non controlling interest 0
Total equity 12672854000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1316358000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 0
Total non-current financial liabilities 1316358000
Provisions, non-current 33872000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 367000
Total non-current liabilities 1350597000
Current liabilities
Current financial liabilities
Borrowings, current 426033000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 110234000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2110687000
Total Trade payable 2220921000
Other current financial liabilities 0
Total current financial liabilities 2646954000
Other current liabilities 185082000
Provisions, current 23660000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 2855696000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 4206293000
Total equity and liabilites 16879147000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be classified to profit or loss 16675000 -7513000
Total Amount of items that will not be reclassified to profit and loss 16675000 -7513000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 16675000 -7513000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 955648000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 145401000
Adjustments for decrease (increase) in inventories -621454000
Adjustments for decrease (increase) in trade receivables, current -490660000
Adjustments for decrease (increase) in trade receivables, non-current 68411000
Adjustments for decrease (increase) in other current assets 45219000
Adjustments for decrease (increase) in other non-current assets 3198000
Adjustments for other financial assets, non-current 16939000
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 0
Adjustments for increase (decrease) in trade payables, non-current -67823000
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 345458000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 32450000
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -58488000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -581349000
Net cash flows from (used in) operations 374299000
Dividends received 0
Interest paid 172774000
Interest received 0
Income taxes paid (refund) 9374000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 192151000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 1501080000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 1044385000
Dividends received 0
Interest received 187386000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -269309000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 285558000
Repayments of borrowings 2207000
Payments of lease liabilities 0
Dividends paid 0
Interest paid 31134000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 252217000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 175059000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 175059000
Cash and cash equivalents cash flow statement at beginning of period 36009000
Cash and cash equivalents cash flow statement at end of period 211068000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Statement on impact of audit qualification
Auditor's opinion Qualified opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Singhi and Co. Yes 31-Aug-2025


Financial details
Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income 9532991000 9532991000
2 Total Expenditure 8536423000 8536423000
3 Net Profit/(Loss) 996568000 996568000
4 Earnings Per Share 19.65 19.65
5 Total Assets 16879147000 16879147000
6 Total Liabilities 4206293000 4206293000
7 Net Worth 12672854000 12672854000


Audit qualification
Sr. Details of Audit Qualification Type of Audit Qualification Frequency of qualification For Audit Qualification(s) where the impact is quantified by the auditor For Audit Qualification(s) where the impact is not quantified by the auditor
Management's Views (i) Management's estimation on the impact of audit qualification (ii) If management is unable to estimate the impact, reasons for the same Auditors' Comments on (i) or (ii) above
1 Textual Information(1) Qualified opinion Repetitive Textual Information(2) Textual Information(3) Textual Information(4) Textual Information(5)


Text Block
Textual Information(1) The Consolidated Financial Statements for the year ended March 31, 2025 include the nfinancial statements for the year ended March 31, 2025, of the following subsidiary ncompames: n(i) Orchid Pharmaceuticals Inc., USA n(ii) Bexel Pharmaceuticals Inc., USA n(iii)Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa (Upto 31 sl nJanuary 2024) n(iv) Diakron Pharmaceuticals, Inc. USA n nWe did not audit the financial statements of the above subsidiaries whose financial statements nreflect total Assets of RS.349.09 Lakhs as at March 31, 2025, total revenue from operations of Rs. nNil, total comprehensive income after tax of Rs.(-) 634.35 Lakhs for the year ended March 31,2025 nand net cash flows amounting to Rs. Nil for the year ended on that date as considered in the nconsolidated financial statements. nThe financial statements of the above subsidiaries are unaudited and have been furnished to us nby the management and our opinion on the Consolidated financial statements, in so far as it relates nto the amounts and disclosures included in respect of the subsidiaries and associate, is based nsolely on such unaudited financial statements. Accordingly, we do not express any opinion on the ncompleteness and true and fair view of the financial statements, including adjustments, if any, nrequired on the carrying amount of assets and liabilities of the above subsidiaries and associate nand foreign currency translation reserve as at March 31,2025 included in the consolidated financial nstatements. This has also been qualified in the Limited Review reports of the earlier quarters and naudit reports of the earlier years, audited by the predecessor auditor.
Textual Information(2) Not Applicable
Textual Information(3) Not Applicable
Textual Information(4) The subsidiaries of the Company are located in USA and South Africa. Audit is not compulsory for companies in USA, if they are not publicly traded Orchid Pharmaceuticals SA, Proprietary, Limited, South Africa have been closed till January 2024. Orchid Pharmaceauticals Inc is now audited upto March 31, 2023. Further transactions in majority of the above subsidiaries are either Nil or very minimum. Hence the management has used unaudited nfinancials for the purpose of consolidation.
Textual Information(5) Refer, Basis for Qualified Opinion, in our audit report. n


Signatories detail
Name of CEO / Managing director Manish Dhanuka
Name of CFO Sunil Kumar Gupta
Name of audit committee chairman Manoj Goyal
Name of statutory auditor Singhi and Co.
Name of other signatory, if any, with designation
Place Gurugram
Date 26-May-2025